CA 19-9
| Material: | 1 ml serum (stability in serum at 4°C – 8°C: > 14 days) 1 ml lithium-heparin plasma, EDTA-plasma |
| Methods: | Ligandenassays → Chemilumineszenz-Immunoassay (CLIA) | Reference range | < 37 U/ml |
| Indication | Therapy and progress checks of pancreas carcinoma, hepatobiliary carcinoma. Differential diagnosis of liver round lesions (with AFP) and as second marker for colon- and rectal carcinomas. |
| Please note | Simultaneous determination of CA 19-9 and CEA increases the sensitivity for gastrointestinal tumors. It is also increased in case of cholestasis, cystic fibrosis, during pregnancy and during menstruation. There is no CA 19-9 expression in persons with blood group Lewis-negative (3 – 7 % of the population), hence it will not be detected in the blood (Caution: false-negative test results). |
| Accredited | ja |
More Results for the letter C
- C-peptide in the serum (CPEP)
- C1-esterase inhibitor (C1-INH) (C1EA, C1EH)
- Activity evaluation, protein evaluation
- C2-complement (C2S)
- C3-complement in the serum (C3)
- C3-nephritis factor (C3NF)
- C3NeF
- C4-complement in the serum (C4)
- CA 125 (CA 125)
- CA 15-3 (CA15)
- CA 19-9 (CA19)
- CA 72-4 (CA72)
- Cadmium (CAD)
- Cd
- Caeruloplasmin (α2-) (CAER(a2))
- Caffeine (COFF)
- Calcitonin (CALC)
- hCT, human calcitonin
- Calcium in serum (CA)
- Ca
- Calcium in urine (CAU)
- Calcium, ionized, in serum (CAI)
- Calprotectin (ECALP)
- Calymmatobacterium granulomatis (CALY)
- Donovaniosis
- Campylobacter jejuni/coli infection (KCAMP, ECAMP, CAMPG, CAMPA)
- Canary serum, feather, excrement antibodies (IgG) (CANA)
- Candida infection (KCAND)
- Cannabinoids (CANN)
- Tetrahydrocannabinol, delta-9 THC, cannabis, weed, marihuana, hash
- Carbamazepine (CARB)
- Carboxyhemoglobin (COHB)
- CO-Hb
- Cardiac muscle antibodies (HMA)
- Carnitine ratio: Acyl carnitine / free carnitine (CARNF)
- Carotene (β-) (CARO(b))
- Group of carotenoids with provitamine A activity
- Cartilage autoantibodies (KNOR)
- Catecholamines in plasma (KATP)